March 2026– date –
-
From Beginner to Expert | Bispecific Antibody Drug Series A1: What Are Bispecific Antibody Drugs? A Thorough Introduction from the Basics
Bispecific antibody drugs are now one of the most important themes in the evolution of cancer therapy and antibody therapeutics. Over the past several years, they have rapidly increased in prominence. In hematologic malignancies, they ar... -
From Beginner to Expert | Bispecific Antibody Drug Series A0: What This Series Will Help You Understand
Bispecific antibody drugs have become one of the most prominent areas in cancer therapy over the past several years. If we only follow headlines, we often see striking phrases such as “a new antibody that brings T cells to cancer,” “a ne... -
Frontier of Therapy Series: Training Immunity to Fight Cancer | The Full Picture of CAR-T (From Beginner to Expert): Complete Index and Series Overview
This article serves as the complete index page for the CAR-T series now that the series has been completed. It is designed as a single entry point that allows readers to see the full picture, from the basics to expert-level implementatio... -
Frontier of Therapy Series: Training Immunity to Fight Cancer: The Full Picture of CAR-T (From Beginner to Expert) B6: What Defines a Winning Commercialization Strategy for CAR-T? Practical Implementation Across COGS, Supply Chain, Site Requirements, and Regulation
In A5 and B5, we explored how in vivo CAR-T is emerging not simply as a novel scientific idea, but as a possible answer to the structural problems of manufacturing, logistics, and access. In A6, we translated that trend into the patient ... -
Frontier of Therapy Series: Training Immunity to Fight Cancer: The Full Picture of CAR-T (From Beginner to Expert) A6: Why Is CAR-T So Expensive? The Reality of Manufacturing, Patient Access, and the Future Shaped by Next-Generation Technologies
CAR-T therapy is one of the cancer treatments that has attracted particularly strong expectations in recent years. In fact, in relapsed or refractory hematologic malignancies, it can produce deep responses that were difficult to achieve ... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | B5: Implementing In Vivo CAR (Delivery × Control × Safety × CMC/Reg) — The Real Hard Problems of “Making CAR Cells Inside the Body” [Expert]
If you want the beginner version first:→ A5: What is in vivo CAR? “Making CAR cells inside the body” explained simply “In Vivo CAR Implementation Stack” Delivery (tLNP/vector, targeting, biodistribution) Control (dose-dependent, repeat d... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | A5: What Is In Vivo CAR? “Making CAR Cells Inside the Body” Explained Simply [Beginner]
Prefer the beginner overview first?→ A0: What is CAR-T therapy? The big picture + index→ A4: Why CAR-T Is Expanding Beyond Cancer (Autoimmunity as an “Immune Reset” Concept) “In vivo CAR at a glance: dose → in-body CAR expression → trans... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | B4: Autoimmune CAR-T Frontier (Design Logic, Disease Buckets, and Company Landscape) [Expert]
Prefer the overview first?→ A4: Why CAR-T expands beyond cancer (autoimmunity as “reset”) “Autoimmune CAR: Reset Toolkit (Target × Durability × Safety)” Executive summary Autoimmune CAR-T is shifting the goal from “killing tumor cells” t... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | A4: Why CAR-T Is Expanding Beyond Cancer (Autoimmunity as an “Immune Reset” Concept) [Beginner]
New here?→ A0: What is CAR-T therapy? The big picture + index (Coming from solid tumors?)→ A3: Why solid tumors are hard for CAR-T→ B3: Solid-tumor CAR-T design toolkit “From Suppression to Reset: Why CAR-T Moves Beyond Cancer” The short... -
Oncology Drug Approval News Flash FDA approves nivolumab (Opdivo) with AVD chemotherapy for previously untreated advanced classical Hodgkin lymphoma (and converts prior accelerated approvals in relapsed/refractory cHL to traditional approval)
On March 20, 2026, the U.S. FDA approved nivolumab (Opdivo) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for adults and pediatric patients aged 12 years and older with previously untreated, Stage III or IV classica... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | B3: How Solid-Tumor CAR-T Tries to Win (Next-Gen Design: Multi-Target, Logic Gates, Armoring, Local Delivery) [Expert]
Prefer the beginner overview first?→ A3: Why solid tumors are hard for CAR-T (the 3 barriers) “Solid-Tumor CAR-T Design Toolkit to Beat 3 Barriers” (Trafficking / TME resistance / Target & safety) Executive summary Solid-tumor CAR-T ... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | A3: Why Solid Tumors Are Hard for CAR-T — The 3 Core Barriers [Beginner]
New here?→ A0: What is CAR-T therapy? The big picture + index→ A1: Where CAR-T is used today (blood cancers first) Deep dive next (B3): next-gen CAR engineering to overcome these barriers (multi-target, logic-gated, armored, local delive... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | B2: Toxicity Management, Site Operations & Long-Term Safety (Including Regulatory Logic) [Expert]
Prefer the beginner overview first?→ A0: What is CAR-T therapy? The big picture + index→ A2: CAR-T side effects without panic (what happens, what to monitor) “CAR-T Toxicity Management: Timeline × Actions × Follow-Up”Left: Day 0–14 (CRS/... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | A2: CAR-T Side Effects Without Panic — What Can Happen & What to Monitor [Beginner]
New here? Start with the basics and where CAR-T is used today.→ A0: What Is CAR-T Therapy? The Big Picture + Series Index→ A1: Where CAR-T Is Used Today — Blood Cancers First Want the deep dive (B2)? We will cover severity grading concep... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | B1: FDA-Approved CAR-T Landscape (Products, Targets, Companies, Label Logic) [Expert]
Prefer the beginner overview first?→ A0: What is CAR-T therapy? The big picture + index→ A1: Where CAR-T is used today (blood cancers first) Executive summary FDA-approved oncology CAR-T products cluster around two core targets: CD19 (B-... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | A1: Where CAR-T Is Used Today — The Big Picture (Blood Cancers First) [Beginner]
New here? If you haven’t read the introduction, it will make this post much easier to follow.→ A0: What Is CAR-T Therapy? The Big Picture + Series Index Want the deep dive? The expert post (B1) will organize FDA-approved CAR-T products b... -
Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | A0: What Is CAR-T Therapy? The Big Picture, in Plain Language [Beginner]
How to use this series (two-layer linkage: Beginner → Expert) This series explains CAR-T therapy in a stepwise way so that readers who are new to the term can first grasp the big picture (Layer A), and then move to the expert layer (Laye... -
Oncology Drug Approval News Flash FDA approves teclistamab (Tecvayli) plus daratumumab hyaluronidase-fihj for relapsed/refractory multiple myeloma (and converts Tecvayli monotherapy from accelerated to traditional approval)
On March 5, 2026, the U.S. FDA approved teclistamab (Tecvayli), a BCMA×CD3 bispecific antibody, in combination with daratumumab hyaluronidase-fihj for adults with relapsed or refractory multiple myeloma (RRMM) who have received at least ... -
New Series: Untangling Cancer Worries: Organ-by-Organ Basics at a Glance — Episode 9: Childhood Cancers—The Big Picture and Where Families Can Ask First
“My child seems unusually tired.” “The fever keeps coming back.” “Bruises appear more easily.” Childhood cancers are uncommon, but once the thought appears, family anxiety can escalate fast. This article offers a calm, plain-language ove... -
New Series: Untangling Cancer Worries: Organ-by-Organ Basics at a Glance — Episode 8: Brain Tumors—When Headaches or Seizures Should Be Evaluated
“My headaches are getting worse.” “I had my first seizure.” “I feel my speech is off.” Brain tumors are emotionally charged, and the fear can escalate quickly. This article offers a calm, plain-language overview of how symptoms are commo...
12